Global Biological Defense Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Medical
Publisher : MRA | Format : PDF
Global Biological Defense Market Research Report 2024
Biodefense market refers to the pharmaceuticals, vaccines and antibodies applied in the treatment of a wide range of infectious diseases, whether those diseases emerge naturally or are deliberately introduced as an act of bioterrorism. Biodefense products generally defense against anthrax, smallpox, botulism, radiation/nuclear disasters and other disasters.
In the wake of the 2001 anthrax attacks, the U.S. government set out on a bold path to improve the country’s preparedness for bioterrorism by developing and stockpiling new drugs and vaccines to protect Americans from health emergencies. Since 2004, the US government has provided assistance in the development and manufacturing of products in order to maintain its Strategic National Stockpile (SNS) to counter any bioterror attack.
According to MRAResearch’s new survey, global Biological Defense market is projected to reach US$ 1452.8 million in 2033, increasing from US$ 1144 million in 2022, with the CAGR of 3.4% during the period of 2023 to 2033. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Biological Defense market research.
The major players in global Biodefense market include Emergent Biosolutions, Hytest, GSK, etc. The top 3 players occupy about 60% shares of the global market. North America, Europe and Asia are key Regions of Sales. Anthrax and Smallpox are main types, with a share about 70%. US Civilian Market is the main application, which holds a share about 55%.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Biological Defense market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
SIGA Technologies
Ichor Medical Systems
Emergent BioSolutions
Elusys Therapeutics
DynPort Vaccine Company
Altimmune
Cleveland BioLabs
Bavarian Nordic
Alnylam Pharmaceuticals
Achaogen
Alexeter Technologies
ANP Technologies
PathSensors
New Horizons Diagnostics
BBI Detection
Segment by Type
Anthrax
Small Pox
Botox
Radiation / Nuclear
Other
Military
Civilian
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Biological Defense report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source
In the wake of the 2001 anthrax attacks, the U.S. government set out on a bold path to improve the country’s preparedness for bioterrorism by developing and stockpiling new drugs and vaccines to protect Americans from health emergencies. Since 2004, the US government has provided assistance in the development and manufacturing of products in order to maintain its Strategic National Stockpile (SNS) to counter any bioterror attack.
According to MRAResearch’s new survey, global Biological Defense market is projected to reach US$ 1452.8 million in 2033, increasing from US$ 1144 million in 2022, with the CAGR of 3.4% during the period of 2023 to 2033. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Biological Defense market research.
The major players in global Biodefense market include Emergent Biosolutions, Hytest, GSK, etc. The top 3 players occupy about 60% shares of the global market. North America, Europe and Asia are key Regions of Sales. Anthrax and Smallpox are main types, with a share about 70%. US Civilian Market is the main application, which holds a share about 55%.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Biological Defense market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
SIGA Technologies
Ichor Medical Systems
Emergent BioSolutions
Elusys Therapeutics
DynPort Vaccine Company
Altimmune
Cleveland BioLabs
Bavarian Nordic
Alnylam Pharmaceuticals
Achaogen
Alexeter Technologies
ANP Technologies
PathSensors
New Horizons Diagnostics
BBI Detection
Segment by Type
Anthrax
Small Pox
Botox
Radiation / Nuclear
Other
Segment by Application
Military
Civilian
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Biological Defense report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source